{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,30]],"date-time":"2024-12-30T18:21:12Z","timestamp":1735582872884},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2011,8,2]],"date-time":"2011-08-02T00:00:00Z","timestamp":1312243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Hematol Malig Rep"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s11899-011-0095-9","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T04:28:08Z","timestamp":1312172888000},"page":"216-221","source":"Crossref","is-referenced-by-count":7,"title":["Recent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma"],"prefix":"10.1007","volume":"6","author":[{"given":"Marlene","family":"Troch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Kiesewetter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,8,2]]},"reference":[{"issue":"6","key":"95_CR1","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","volume":"60","author":"A Ruskon\u00e9-Fourmestraux","year":"2011","unstructured":"Ruskon\u00e9-Fourmestraux A, Fischbach W, Aleman B, et al. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60(6):747\u201358.","journal-title":"Gut"},{"key":"95_CR2","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1182\/blood.V95.3.802.003k19_802_806","volume":"95","author":"C Thieblemont","year":"2000","unstructured":"Thieblemont C, Berger F, Dumontet C, et al. Mucosa associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood. 2000;95:802\u20136.","journal-title":"Blood"},{"key":"95_CR3","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","volume":"101","author":"E Zucca","year":"2003","unstructured":"Zucca E, Conconi A, Pedrinis E, et al. Non-gastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489\u201395.","journal-title":"Blood"},{"key":"95_CR4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1634\/theoncologist.11-3-285","volume":"11","author":"L Arcaini","year":"2006","unstructured":"Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone-B-cell MALT lymphoma: Prognostic value of disease dissemination. Oncologist. 2006;11:285\u201391.","journal-title":"Oncologist"},{"key":"95_CR5","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.2006.06.0723","volume":"24","author":"M Raderer","year":"2006","unstructured":"Raderer M, W\u00f6hrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: A single center experience. J Clin Oncol. 2006;24:3136\u201341.","journal-title":"J Clin Oncol"},{"key":"95_CR6","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1158\/1078-0432.CCR-04-2282","volume":"11","author":"M Raderer","year":"2005","unstructured":"Raderer M, Streubel B, W\u00f6hrer S, et al. High relapse rate in patients with MALT lymphoma warrants lifelong follow-up. Clin Cancer Res. 2005;11:3349\u201352.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"95_CR7","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.2005.02.9025","volume":"24","author":"B Gr\u00fcnberger","year":"2006","unstructured":"Gr\u00fcnberger B, W\u00f6hrer S, Streubel B, et al. Antibiotic treatment is not effective in patients infected with Helicobacter pylori suffering from extragastric MALT lymphoma. J Clin Oncol. 2006;24(9):1370\u20135.","journal-title":"J Clin Oncol."},{"issue":"1","key":"95_CR8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/annonc\/mdm561","volume":"19","author":"AJ Ferreri","year":"2008","unstructured":"Ferreri AJ, Dognini GP, Ponzoni M, et al. Chlamydia-psittaci-eradicating antibiotic therapy in patients with advanced-stage ocular adnexal MALT lymphoma. Ann Oncol. 2008;19(1):194\u20135.","journal-title":"Ann Oncol"},{"issue":"5","key":"95_CR9","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1111\/j.1349-7006.2010.01502.x","volume":"101","author":"TM Kim","year":"2010","unstructured":"Kim TM, Kim KH, Lee MJ. First-line therapy with doxycycline in ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective analysis of clinical predictors. Cancer Sci. 2010;101(5):1199\u2013203.","journal-title":"Cancer Sci"},{"issue":"11","key":"95_CR10","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.3109\/10428194.2010.513751","volume":"51","author":"D Zhang","year":"2010","unstructured":"Zhang D, Dong L, Li H, et al. Ocular adnexal mucosa-associated lymphoid tissue lymphoma in Northern China: high frequency of numerical chromosomal changes and no evidence of an association with Chlamydia psittaci. Leuk Lymphoma. 2010;51(11):2031\u20138.","journal-title":"Leuk Lymphoma."},{"issue":"1","key":"95_CR11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1309\/AJCPXMDRT1SY6KIV","volume":"135","author":"A Aigelsreiter","year":"2011","unstructured":"Aigelsreiter A, Gerlza T, Deutsch AJ, et al. Chlamydia psittaci Infection in nongastrointestinal extranodal MALT lymphomas and their precursor lesions. Am J Clin Pathol. 2011;135(1):70\u20135.","journal-title":"Am J Clin Pathol."},{"issue":"2","key":"95_CR12","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","volume":"150","author":"S Govi","year":"2010","unstructured":"\u2022 Govi S, Dognini GP, Licata G, Crocchiolo R, et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol. 2010;150(2):226\u20139. This is a provocative and hypothesis-generating article on the role of clarithromycin in MALT lymphoma.","journal-title":"Br J Haematol"},{"issue":"3","key":"95_CR13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1378\/chest.09-2358","volume":"138","author":"Y Ishimatsu","year":"2010","unstructured":"Ishimatsu Y, Mukae H, Matsumoto K, et al. Two cases with pulmonary mucosa-associated lymphoid tissue lymphoma successfully treated with clarithromycin. Chest. 2010;138(3):730\u20133.","journal-title":"Chest."},{"issue":"6","key":"95_CR14","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s00277-009-0875-7","volume":"89","author":"SY Oh","year":"2010","unstructured":"\u2022 Oh SY, Kim WS, Kim JS, et al. Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2010;89(6):563\u20138. This is a retrospective analysis of treatment of pulmonary MALT lymphoma.","journal-title":"Ann Hematol"},{"issue":"1","key":"95_CR15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1365-2141.2010.08429.x","volume":"152","author":"S Bayraktar","year":"2011","unstructured":"\u2022 Bayraktar S, Bayraktar UD, Stefanovic A, Lossos IS. Primary ocular adnexal mucosa-associated lymphoid tissue lymphoma (MALT): single institution experience in a large cohort of patients. Br J Haematol. 2011;152(1):72\u201380. This is one of the largest (retrospective) series on ocular adnexal lymphomas.","journal-title":"Br J Haematol"},{"key":"95_CR16","doi-asserted-by":"crossref","unstructured":"Goda JS, Le LW, Lapperriere NJ, et al. Localized orbital mucosa-associated lymphoma tissue lymphoma managed with primary radiation therapy: efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2011 Jun 1 (Epub ahead of print).","DOI":"10.1016\/j.ijrobp.2011.03.050"},{"issue":"16","key":"95_CR17","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","volume":"116","author":"JS Goda","year":"2010","unstructured":"Goda JS, Gospodarowicz M, Pintilie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116(16):3815\u201324.","journal-title":"Cancer"},{"issue":"4","key":"95_CR18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/annonc\/mdn692","volume":"20","author":"B Esmaeli","year":"2009","unstructured":"Esmaeli B, McLaughlin P, Pro B, et al. Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal lymphoma. Ann Oncol. 2009;20(4):709\u201314.","journal-title":"Ann Oncol."},{"issue":"1","key":"95_CR19","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3109\/10428194.2010.534519","volume":"52","author":"M Hoffmann","year":"2011","unstructured":"Hoffmann M, Troch M, Eidherr H, et al. 90Y-ibritumomab tiuxetan (Zevalin) in heavily pretreated patients with mucosa associated lymphoid tissue lymphoma. Leuk Lymphoma. 2011;52(1):42\u20135.","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"95_CR20","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/annonc\/mdm457","volume":"19","author":"EK Song","year":"2008","unstructured":"Song EK, Kim SY, Kim TM, et al. Efficacy of chemotherapy as a first-line treatment in ocular adnexal extranodal marginal zone B-cell lymphoma. Ann Oncol. 2008;19(2):242\u20136.","journal-title":"Ann Oncol."},{"key":"95_CR21","doi-asserted-by":"crossref","unstructured":"Gill H, Chim CS, Au WY, et al. Non-gastric marginal zone B cell lymphoma: clinicopathologic features and treatment results Ann Hematol. 2011 Apr 8 (Epub ahead of print).","DOI":"10.1007\/s00277-011-1226-z"},{"issue":"22","key":"95_CR22","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","volume":"115","author":"A Salar","year":"2009","unstructured":"Salar A, Domingo-Domenech E, Estany C, et al. Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type. Cancer. 2009;115(22):5210\u20137.","journal-title":"Cancer"},{"issue":"12","key":"95_CR23","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1080\/10428190802510331","volume":"49","author":"C Kalpadakis","year":"2008","unstructured":"Kalpadakis C, Pangalis GA, Vassilakopoulos TP, et al. Non-gastric extra-nodal marginal zone lymphomas\u2013a single centre experience on 76 patients. Leuk Lymphoma. 2008;49(12):2308\u201315.","journal-title":"Leuk Lymphoma."},{"issue":"18","key":"95_CR24","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","volume":"20","author":"G J\u00e4ger","year":"2002","unstructured":"J\u00e4ger G, Neumeister P, Brezinschek R, et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study. J Clin Oncol. 2002;20(18):3872\u20137.","journal-title":"J Clin Oncol"},{"issue":"3","key":"95_CR25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1093\/annonc\/mdq416","volume":"22","author":"A Conconi","year":"2011","unstructured":"Conconi A, Martinelli G. Lopez-Guillermo A Clinical activity of bortezomib in relapsed\/refractory MALT lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011;22(3):689\u201395.","journal-title":"Ann Oncol."},{"issue":"5","key":"95_CR26","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3324\/haematol.2008.001537","volume":"94","author":"M Troch","year":"2009","unstructured":"Troch M, Jonak C, M\u00fcllauer L, et al. A phase II study of bortezomib in patients with MALT lymphoma. Haematologica. 2009;94(5):738\u201342.","journal-title":"Haematologica"}],"container-title":["Current Hematologic Malignancy Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0095-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11899-011-0095-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11899-011-0095-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T12:09:42Z","timestamp":1712664582000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11899-011-0095-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,2]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s11899-011-0095-9","relation":{},"ISSN":["1558-8211","1558-822X"],"issn-type":[{"value":"1558-8211","type":"print"},{"value":"1558-822X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,2]]}}}